Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in Taiwan.

Autor:	Huang YC; Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Pharmacy, Taipei Medical University, Shuang Ho Hospital, New Taipei City, Taiwan. Electronic address: d08451001@ntu.edu.tw., Hsiao FY; Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: fyshsiao@ntu.edu.tw., Guan ST; Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; Health Data Research Center, National Taiwan University, Taipei, Taiwan. Electronic address: john.gst03@gmail.com., Yao M; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: yaomingmd@gmail.com., Liu CJ; Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Emergency and Critical Care Medicine, School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan. Electronic address: chiajenliu@gmail.com., Chen TT; Division of Hematology and Oncology, China Medical University Hospital, Taiwan. Electronic address: little_zi2000@yahoo.com.tw., Lin TL; Division of Hematology, Chang Gung Memorial Hospital, Linkou, Taiwan. Electronic address: ldl2605@cgmh.org.tw., Liu YC; Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Taiwan. Electronic address: ycliu@kmu.edu.tw., Chen TY; Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, Taiwan. Electronic address: teresa@mail.ncku.edu.tw., Hong YC; Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Electronic address: ychong@vghks.gov.tw., Ma MC; Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan. Electronic address: mingchun123@gmail.com., Tan TD; Department of Hematopoietic Stem Cell Transplantation and Cell Therapy, Koo Foundation Sun Yat-Sen Cancer Center, Taiwan. Electronic address: trander@kfsyscc.org., Wang CC; Division of Hematology-Oncology, Changhua Christian Hospital, Taiwan. Electronic address: 114992@cch.org.tw., Wu YY; Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taiwan. Electronic address: rq0922@gmail.com., Liao PW; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taiwan. Electronic address: rs60809st@hotmail.com., Wu YF; Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Hualien, Taiwan. Electronic address: wuyifeng43@gmail.com., Chen YY; Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan. Electronic address: chenyiyang0406@gmail.com., Yu YB; Division of Oncology-Hematology, Far Eastern Memorial Hospital, Taiwan. Electronic address: fishie.yu@gmail.com., Hsieh YY; Department of Hematology and Oncology, Taipei Medical University, Shuang Ho Hospital, Taiwan. Electronic address: alecto39@gmail.com., Lee MY; Division of Hematology and Oncology, Department of Internal Medicine, Chia-Yi Christian Hospital, Taiwan. Electronic address: cych05825@gmail.com., Liu JH; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Electronic address: b8702037@gmail.com., Lin SW; Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Pharmacy, National Taiwan University Cancer Center, Taipei, Taiwan. Electronic address: shuwenlin@ntu.edu.tw., Ko BS; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taiwan; School of Medicine, College of Medicine, National Taiwan University, Taiwan. Electronic address: kevinkomd@gmail.com.
Jazyk:	angličtina
Zdroj:	Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi [J Microbiol Immunol Infect] 2024 Jun; Vol. 57 (3), pp. 365-374. Date of Electronic Publication: 2024 Mar 06.
DOI:	10.1016/j.jmii.2024.02.005
Abstrakt:	Background: Cytomegalovirus (CMV) can cause infection and critical diseases in hematopoietic stem cell transplantation (HSCT) recipients. This study aimed to explore the cumulative incidence and risk factors for CMV infection and disease among HSCT recipients in Taiwan. Methods: This retrospective cohort study using the Taiwan Blood and Marrow Transplantation Registry (TBMTR) included HSCT recipients between 2009 and 2018 in Taiwan. The primary outcome was cumulative incidence of CMV infection or disease at day 100 after HSCT. Secondary outcomes included day 180 cumulative incidence of CMV infection or disease, infection sites, risk factors for CMV infection or disease, survival analysis, and overall survival after CMV infection and disease. Results: There were 4394 HSCT recipients included in the study (2044 auto-HSCT and 2350 allo-HSCT). The cumulative incidence of CMV infection and disease was significantly higher in allo-HSCT than in auto-HSCT patients at day 100 (53.7% vs. 6.0%, P < 0.0001 and 6.1% vs. 0.9%, P < 0.0001). Use of ATG (HR 1.819, p < 0.0001), recipient CMV serostatus positive (HR 2.631, p < 0.0001) and acute GVHD grades ≥ II (HR 1.563, p < 0.0001) were risk factors for CMV infection, while matched donor (HR 0.856, p = 0.0180) and myeloablative conditioning (MAC) (HR 0.674, p < 0.0001) were protective factors. Conclusion: The study revealed a significant disparity in terms of the incidence, risk factors, and clinical outcomes of CMV infection and disease between auto and allo-HSCT patients. These findings underscore the importance of considering these factors in the management of HSCT recipients to improve outcomes related to CMV infections. Competing Interests: Declaration of competing interest The authors declare no conflict of interest. (Copyright © 2024. Published by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu